Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03580928
Recruitment Status : Recruiting
First Posted : July 10, 2018
Last Update Posted : November 14, 2019
Sponsor:
Collaborators:
Acerta Pharma, LLC
Genentech, Inc.
Information provided by (Responsible Party):
Matthew S. Davids, MD, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 31, 2022
Estimated Study Completion Date : January 31, 2026